That passphrase isn't right. Check your invitation email, or contact harry.massey@e4l.com.
Confidential. For accredited investors only. Securities offered under Rule 506(c) of Regulation D; accredited status is verified before any subscription is accepted. Site access is granted by E4L, Inc.
We believe physics is becoming the defining paradigm in health this decade. Biology runs on chemistry, and chemistry runs on physics — the fields, voltage and information underneath every cell. E4L is one of the first companies building products from a physics-first view of the body: an AI platform, a wearable, drinkable information, and a practitioner network that detect, correct, and protect your energy. Additive to medicine, never against it.
Confidential — for accredited investors only (Reg D 506(c); accredited status verified).
From Beyond Medicine — streaming August 2026.
Here is the whole thesis in one line: physics controls chemistry, and chemistry controls biology. Your cells are governed by voltage, fields and information — the physics layer that sits underneath the chemistry medicine has spent a century perfecting. Change the physics and the chemistry follows. E4L is one of the first companies building products from that layer in the body. One equation frames every product we sell:
Information — how clear your body's signals are. Voltage — the charge your cells hold. Resistance — what quietly leaks it away.
A 30-second scan on any phone — voice, tongue, face — reads where energy is draining and returns a Vitality Score out of 100. No needles, no labs, no kit to wait for.
Send the right information back in — a software update for the body: three recommended Infoceuticals, or a program on the GEM or miHealth.
Supportive signals run quietly in the background through the day, so the gains hold — and every re-scan refreshes the plan. That loop is the subscription.
The GEM · $397 — the wearable that detects, corrects and protects energy and emotions, all day.
Infoceuticals · from $33 — drops that carry information back to the body; matched to each scan, reordered on a 3–4 week cycle.
miHealth · $5,000 — the professional-grade handheld that practitioners build sessions around.
Behind all of it sits FIELD — the AI platform trained on 1M+ proprietary scans. E4L owns FIELD outright, through the NES Health LLC subsidiary it acquired. The devices, the drops, the app, the practitioners and the film audience are the ecosystem that feeds it.
Drug discovery follows "Eroom's Law" — the cost of a new drug roughly doubles every nine years while output falls. The chemical curve has flattened; the physics curve is just beginning.
If biochemistry is the hardware, the body's fields and voltage are the software. The thesis holds that working at the information layer influences the physical output — faster, and at a fraction of the metabolic cost.
Once the hardware is in a customer's hands, much of the "correction" is information — a software update for the body. That is how a physical-products company earns 80–85% gross margins. This is a modeled blended margin — COGS already reflects payment processing (~2%), fulfillment and certification/onboarding, not bill-of-materials only.
Read the full thesis — The Physics-First Healthcare Transition
Harry Massey spent seven years bedridden with severe fatigue. Conventional approaches had no answers, so he asked a different question — not which chemicals are out of balance, but why doesn't my body have the energy to fix them? He spent the next two decades building the answer: the Infoceutical library, the miHealth, the GEM, and the practitioner platform now evolving into FIELD.
He is the author of four books on bioenergetics, including Decoding the Human Body-Field (with Peter Fraser, Inner Traditions, 2008). His story is now a feature documentary: Beyond Medicine, directed by Emmy Award-winning filmmaker Mitchell Stuart (HQ Creative) — whose work spans Taylor Swift, Lady Gaga and The Who, with more than 100 industry honors — streaming August 2026, and pointed straight at the company's funnels.
Harry's recovery is his personal experience, not a product claim.
Who's behind it — question 02
Beyond Medicine · dir. Mitchell Stuart · streams August 2026 (streaming release, not theatrical).
E4L, Inc. is a new company — incorporated in the US in 2026, headquartered in Salt Lake City, with a new operating team. What makes it unusual is what it starts with: it acquired the products, IP, data and customer base of XPO Health / NES Health, the UK bioenergetics pioneer whose founder — Harry — spent two decades building them. The growth engine on top — the GEM wearable, the consumer app, the new miHealth, FIELD and the Beyond Medicine film — is brand new, with zero revenue history, and the forecast treats it that way: every growth number is a stated assumption. What was bought, not rebuilt:
New company. New team. Day-one revenue.
Acquired assets — not inherited claims.
The BWS practitioner platform — the acquired system FIELD evolves from.
Historical customers in the acquired file.
Asset acquisition, 2026Active practitioners transferring with the purchase.
Asset acquisition, 2026Infoceutical wholesale run-rate of the acquired base at close (≈650 × ~$450/mo, 2026) — day-one revenue, and the forecast's opening input.
Management figure at close · model v2.6 inputDebt assumed with the assets — no seller note, no royalty, no deferred purchase price. Legacy liabilities stayed with the old company.
Asset purchase · Disclosure MemorandumDevices open the door; subscriptions, consumables and wholesale own the house. Blended gross margin 80–85% — the value is in the information, not the materials.
| Revenue line | Engine |
|---|---|
| App subscriptions Consumer | Free 30-day trial → Member $10/mo → GEM plan $30/mo (with the GEM) → Guided $90/mo (three Infoceuticals shipped monthly, three-month commitment) |
| GEM wearable Consumer | $397 one-time — each unit seeds a GEM plan subscription |
| Infoceutical consumables Consumer | Cell Driver+ $38/mo delivered (60-day guarantee); Guided $90/mo — three Infoceuticals shipped monthly; singles $33 (three for $99); a re-scan every 30 days refreshes the three and drives reorders |
| miHealth devices Practitioner | $5,000 professional handheld, from a $1,000-deposit 60-day trial |
| BWS / FIELD system Practitioner | Rent-to-own $3,997 down + $397/mo (5 yrs) or $20,000 upfront; most renters convert to ownership early |
| Wholesale consumables Practitioner | ~$450/mo per active practitioner today, rebuilding toward $600/mo (historical peak $720) |
Practitioner system pricing is strategy-call-only on the public site; stated here for investors.
~650 acquired practitioners — each one a storefront for devices, systems and consumables.
Blended gross margin across all six lines.
Model v2.6 · confirmed driversThe GEM app is the gateway, not the destination (free 30-day trial → Member $10 → $30 GEM plan / $90 Guided) — a low-cost front door that turns consumers into buyers of the GEM and infoceuticals, into clients, and moves some up into coaches and practitioners. The revenue engine is the products and the practitioner channel.
Consumer subscription · the funnelThe credibility strategy is to go via the universities: lead with published, peer-reviewed work — and label the pilot honestly.
less oxidative stress in treated cells — blinded, living-cell study.
EXPLORE, 2025 · UC San Diegogenes altered in expression — 717 up, 422 down.
EXPLORE, 2025 · UC San Diegolower self-reported anxiety scores (p=0.007) in the GEM human pilot.
GEM pilot · N=20 · validated surveyslower self-reported fatigue scores in the same pilot.
GEM pilot · N=20 · validated surveysThe UCSD results are cellular findings — biological effects on energy and oxidative-stress markers, not clinical outcomes in people. The GEM pilot is observational with no control group — directional, not definitive; a controlled study is in the funded R&D plan. These are wellbeing measures, not disease endpoints.
A clean regulatory track record. Across 20+ years of commercial history, the acquired products have passed three FDA inspections with no issues — including an in-person infoceuticals inspection and repeated, stricter customs/FDA import reviews. The miHealth handheld is in the final stages of FDA over-the-counter clearance for pain relief — a genuine milestone in progress. The GEM is positioned as a performance and wellness product, and the consumer lines make structure/function and wellbeing claims only. Regulatory exposure is minimal.
UC San Diego School of Medicine — where researchers conducted the EXPLORE cell study. Prof. Hemal Patel is E4L's scientific advisor.
"A cell has no mind. It can't believe. There's no placebo to hide behind."
— Prof. Hemal Patel, PhD, UCSD; scientific advisor to E4L. His starting point: your DNA is the same alive or dead — the difference is energy.
Papers, protocols & pipeline — The ProofRevenue starts in Q4 2026 — $2.7M (Q4 2026, the first quarter of revenue) — then $16.0M in FY2027, the first full year, scaling to $134.7M by FY2031. Built bottoms-up from confirmed drivers across all six lines.
| Revenue | Q4 2026 | FY27 | FY28 | FY29 | FY30 | FY31 |
|---|---|---|---|---|---|---|
| Total | $2.7M | $16.0M | $34.3M | $57.9M | $94.0M | $134.7M |
Profitable early — and every quarter after: +$1.7M FY27 rising to +$39M FY31 (29% margin), after funding a disciplined R&D reinvestment. Blended gross margin 80–85% throughout.
The minimum cash position across the whole plan — building to $67M by end-2031 after tax, with no further raise assumed.
The acquired base grows on a ~4-sales-per-rep cadence with 8%/yr churn modeled; consumer lines compound behind the film and app funnels.
Global wellness economy (2024), forecast $9.8T by 2029.
Global Wellness Institute, Global Wellness Economy Monitor 2025Wearable technology market (2025), projected $230.0B by 2033.
Grand View Research, Wearable Technology MarketDigital health market (2024), projected $573.5B by 2030.
MarketsandMarkets, Digital Health MarketE4L sits where these overlap: a wearable + digital-health platform sold into the wellness economy. The company TAM/SAM/SOM build from these sources is in the data room.
Projections are illustrative, based on management assumptions; actual results will differ. Prepared August 2026 from the bottoms-up quarterly model, v2.6.
Every number on this site is deliberately conservative — a products business we can defend line by line. None of it counts the reason E4L could become something far larger.
E4L's rarest asset is a capability no one else has assembled — and one the company owns: mapping the body's physics and inventing new products from it, and — as the FIELD dataset grows — mapping how specific fields change cells. That owned cellular-field-mapping capability is licensable. Pharma, device and longevity companies would pay to know which field does what. We have modeled none of that licensing revenue. (The upside rests on E4L's owned cellular-field-mapping capability.)
Zoom out and three curves are converging at once — AI trained on biological data, quantum-grade sensors, and the recognition that physics governs biology. A first mover holding the data and the patents at the interface between intelligence and the cell has a genuine shot at defining the category — a potentially trillion-dollar outcome. That is the honest bull case. It is a moonshot, and it is explicitly NOT in our forecast; our numbers are the conservative floor beneath it.
The full thesis — The Physics-First Healthcare TransitionLicensing revenue in the forecast — the field-mapping upside is entirely excluded until deals are signed and modelable.
Model v2.6 · deliberately conservativeFirst mover mapping the body's physics and inventing products from it — the position the moonshot is built on.
Category-defining capabilityFirst to map the physics of the body.
The floor is a real business; the ceiling is a new category.
E4L Centers LLC — the flagship Energy 4 Life Center in Salt Lake City — is a separately funded company, 50%-owned by E4L, Inc. — which controls it as the LLC’s sole Manager — run by an experienced clinic operator and opening in 2027. It delivers the full method as a premium 7-day program ($15k/$25k), fed by the film, the app and the practitioner network.
E4L, Inc.'s stake in E4L Centers LLC — held for ~$1M of in-kind platform, equipment and team; E4L, Inc. is the sole Manager.
Flagship clinic · Salt Lake CityClinic value and revenue in model v2.6 — the stake, the research pipeline and the franchise rights all sit outside the forecast.
Deliberately conservativeOne modest clinic first. Then a franchise model practitioners already want.
Remaining membership: Massey Developments 10% ($400k cash) · Carla Wittstock 25% ($1M) · Eric Wold 15% (5% purchased, plus 2.5% at signing and 7.5% vesting over 24 months, in an oversight role).
The clinic raises its own capital and its numbers live in its own plan; illustrative and not part of this offering.
CEO & Founder · Chairman. Inventor and architect of the acquired bioenergetic platform; author of four books on bioenergetics, including Decoding the Human Body-Field (2008); subject of Beyond Medicine (streams Aug 2026).
Strategic Execution · Board. PhD business scientist and operator; as CEO she scaled The Targeted Strategies Group from 17 to 125+ professionals and past $11B of in-force policies — Canada's #1 permanent life-insurance brokerage.
CRO & President, Practitioner Channel. Nearly two decades of medical-device commercial leadership across Medtronic, Covidien and US Surgical; most recently COO of Salt Lake City surgical-imaging company Xenocor through fundraising and the Saberscope launch.
VP Supply Chain & Operations. 20+ years scaling regulated medical-device and consumer-health manufacturing — senior operations roles at Ultradent, Spectrum Solutions and MIT45; ISO 13485 / FDA production. Owns hardware and the global supply chain.
Director of Marketing. A decade building growth engines for consumer health and DTC brands — including Organifi during its back-to-back Inc. 500 years — with organic programs scaled from launch to 100K+ monthly visitors.
Head of Product. Builds E4L's consumer AI end-to-end — the GEM diagnostic algorithm, the Vitality scoring engine, computer vision and the Aurora AI Health Coach — concept to working product in months.
Board of directors: three seats, all designated by Harry — Harry Massey (Chairman & CEO) and Susan Kichuk, with the third seat open, earmarked for a major investor or technologist.
Advisors: Prof. Hemal Patel, PhD (UCSD — scientific advisor) · Dr. Zulia Frost (clinical practice).
$5M on a YC-style SAFE · $73M post-money cap + 15% discount — converting at the lower of the two · accredited investors only (Reg D 506(c)). The cap is a negotiated term of this round. With the 15% discount, your effective entry will likely sit below the cap. We intend to raise a priced Series A within ~18 months; if a sale happens first, the same lower-of-cap-or-discount terms apply to the sale price. No escrow, no tranching; the assets are already in the company. E4L is a new company that starts with acquired products, ~650 practitioners and recurring revenue from day one — not a concept waiting for its first customer.
Raising now — round opens with the film and beta app, Aug–Sep 2026.
SAFE (YC style)Post-money cap plus a 15% discount, converting at the lower of the two.
Cap + discount SAFEIntended window for the priced Series A — the conversion event for your SAFE. If a sale comes first, the same lower-of terms apply to the sale price.
Expectation, not a commitmentAccredited investors only — every one verified before closing.
Reg DMilestones to the priced round: film + beta app (Aug 26) → revenue on + sales team (Sep 26) → FY27 revenue ≈$16M → FIELD commercial launch → priced round from strength.
We wrote the diligence questions you'd ask anyway — and answered them in order. Then the model, the deal, and the documents.
Or talk to Harry directly — harry.massey@e4l.com
This page contains illustrative projections and wellness (structure/function) product descriptions only; E4L products are not intended to diagnose, treat, cure, or prevent any disease.